Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
Conditions:
🦠 Tardive Dyskinesia
🗓️ Study Start (Actual) 30 May 2023
🗓️ Primary Completion (Estimated) 30 November 2024
✅ Study Completion (Estimated) 31 December 2024
👥 Enrollment (Estimated) 300
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Brooklyn, New York, United States
📍 Garfield Heights, Ohio, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • For the non-TD group:
    • 1. Prescribed and taking an antipsychotic medication for 90-days or longer.
    • 2. Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome, Huntington disease.
    • 3. Signed an informed consent.
    • 4. Speaks English fluently.

    Exclusion Criteria:

    • 1. Suffered a moderate or severe head injury in the last year;
    • 2. History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol.
    • 3. Severe visual impairment that is cannot be corrected by glasses or contacts.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 21 August 2023
  • First Submitted that Met QC Criteria 21 August 2023
  • First Posted 25 August 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 7 March 2024
  • Last Update Posted 12 March 2024
  • Last Verified March 2024